Bristol’s Sprycel To Launch “Within Days”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA grants dasatinib accelerated approval for all phases of chronic myeloid leukemia in patients resistant to or intolerant of Novartis’ Gleevec.
You may also be interested in...
Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.
Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.
Bristol To Overcome Sprycel Uptake “Resistance” By Encouraging Faster Switching
Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.